Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

The health care sector has yet to see any significant earnings representation, but that will change this week. In fact, pharmaceutical and biotech investors are about to get a real earnings show, as this week will bring reports from some of the major players, in what is probably the busiest week this earnings season.

24/7 Wall St. has put together a preview of some of the top pharma companies reporting their latest results in the coming week. Keep in mind that we are now in the heart of earnings season, which sets a direction for the market.

We have included the consensus earnings estimates from Thomson Reuters, as well as the stock price and trading history for these companies ahead of the report.

Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change reporting dates as well.

[nativounit]

Biogen Inc. (NASDAQ: BIIB) is expected to report its first-quarter results early on Tuesday. The consensus forecast calls for $5.92 in earnings per share (EPS) and revenue of $3.15 billion. Shares of Biogen ended last week at $263.02. The consensus analyst price target is all the way up at $371.97. The 52-week trading range is $244.28 to $370.57.

Eli Lilly and Co. (NYSE: LLY) is set to report its most recent results Tuesday morning as well. The analysts’ consensus estimates are $1.14 in EPS on revenue of $5.49 billion. Shares were changing hands at $79.06 on Friday’s close. The consensus price target is $90.80, and the 52-week range is $73.69 to $89.09.

BioMarin Pharmaceutical Inc.’s (NASDAQ: BMRN) first-quarter results are due late on Wednesday. The consensus forecast calls for a net loss of $0.18 per share and revenue of $348.57 million. The shares ended last week at $82.30. The consensus analyst target is $114.30. The 52-week trading range is $75.81 to $100.51.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to reveal its first-quarter results Thursday morning. The consensus forecast calls for EPS of $1.50 and $922.99 million in revenue. Shares were trading at $107.78 on Friday’s close. The consensus price target is $158.60, while the 52-week range is $96.18 to $149.34.

Bristol-Myers Squibb Co. (NYSE: BMY) also is expected to post its first-quarter results Thursday morning. The consensus forecast calls for EPS of $0.84 and $5.23 billion in revenue. Shares ended last week trading at $51.17 apiece. The consensus price target is $62.00, while the 52-week range is $51.02 to $70.05.

[recirclink id=458094]

AbbVie Inc. (NYSE: ABBV) will share its most recent quarterly results early Thursday. The consensus estimates are $1.80 in EPS and $7.59 billion in revenue. Shares closed at $92.60 on Friday, in a 52-week range of $63.55 to $125.86. The stock has a consensus price target of $121.38.

And Amgen Inc. (NASDAQ: AMGN) will report its most recent quarterly results late Thursday. The consensus forecast is $3.24 in EPS and $5.43 billion in revenue. Shares closed on Friday at $171.56, in a 52-week range of $152.16 to $201.23. The consensus price target is $195.14.

Also see our separate previews of Dow Jones industrial earnings and of the FANGs and more reporting this week.

[wallst_email_signup]